ABL Diagnostics Releases Latest Research Report

ABL Diagnostics has announced the release of a new equity research report by All Invest Securities. The report, dated September 14, 2026, reaffirms the Buy recommendation for the company's shares, maintaining a target price of €8.7. This is supported by the company's strong revenue growth and improved profitability in the first half of 2026. The research note is accessible on the ABL Diagnostics website.

All Invest Securities highlights ABL Diagnostics' confirmed full-year guidance as another positive indicator. The analysis is reserved for professional investors under Directive 2014/65/EU (MiFID II), with distribution subject to regional regulations.

Forward-looking statements in the release acknowledge potential risks, including market changes and economic conditions. ABL Diagnostics clarifies that the press release should not be considered a financial offer or solicitation within any jurisdiction.